Preliminary clinical pharmacokinetics and dose-response to support a phase II dose selection for CX-2009: A masked probody drug conjugate to CD166. This is an ASCO Meeting Abstract from the 2020 ASCO ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results